Literature DB >> 16262592

Attention-deficit/hyperactivity disorder and early-onset substance use disorders.

Jeffrey J Wilson1, Frances R Levin.   

Abstract

In recent years, there has been an increased recognition of the common comorbidity of attention-deficit/ hyperactivity disorder (ADHD) and substance use disorder (SUD) among adolescents and adults. ADHD can be an important factor in the pathogenesis and maintenance of SUD; moreover, retrospective studies suggest that treating ADHD during childhood may prevent the development of SUD. In addition, treatment of ADHD among adults, and possibly adolescents, with SUD can reduce their risk of relapse. Theoretical mechanisms that may explain the relationship between ADHD and SUD are explored in this paper. Current research and recommended clinical practices related to the diagnosis and treatment of ADHD with SUD in adolescents are discussed as well. More research is needed to definitively assess the effectiveness and safety of medications in this population of youths with ADHD and SUD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16262592     DOI: 10.1089/cap.2005.15.751

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  15 in total

Review 1.  Understanding attention-deficit/hyperactivity disorder from childhood to adulthood.

Authors:  Timothy E Wilens; Thomas J Spencer
Journal:  Postgrad Med       Date:  2010-09       Impact factor: 3.840

2.  Chronic treatment with extended release methylphenidate does not alter dopamine systems or increase vulnerability for cocaine self-administration: a study in nonhuman primates.

Authors:  Kathryn E Gill; Peter J Pierre; James Daunais; Allyson J Bennett; Susan Martelle; H Donald Gage; James M Swanson; Michael A Nader; Linda J Porrino
Journal:  Neuropsychopharmacology       Date:  2012-07-18       Impact factor: 7.853

Review 3.  Pharmacological management of attention-deficit hyperactivity disorder in adolescents: special considerations.

Authors:  Philip Hazell
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 4.  Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.

Authors:  Yu-Shu Huang; Ming-Horng Tsai
Journal:  CNS Drugs       Date:  2011-07       Impact factor: 5.749

5.  Externalizing behaviors and cigarette smoking as predictors for use of illicit drugs: a longitudinal study among Finnish adolescent twins.

Authors:  Tellervo Korhonen; Esko Levälahti; Danielle M Dick; Lea Pulkkinen; Richard J Rose; Jaakko Kaprio; Anja C Huizink
Journal:  Twin Res Hum Genet       Date:  2010-12       Impact factor: 1.587

Review 6.  Contributions of serotonin in addiction vulnerability.

Authors:  L G Kirby; F D Zeeb; C A Winstanley
Journal:  Neuropharmacology       Date:  2011-04-03       Impact factor: 5.250

7.  Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood.

Authors:  Salvatore Mannuzza; Rachel G Klein; Nhan L Truong; John L Moulton; Erica R Roizen; Kathryn H Howell; Francisco X Castellanos
Journal:  Am J Psychiatry       Date:  2008-04-01       Impact factor: 18.112

8.  Substance use disorders in children and adolescents with attention-deficit/hyperactivity disorder: implications for treatment and the role of the primary care physician.

Authors:  Himanshu P Upadhyaya
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 9.  [Methylphenidate. Therapy option for adults with ADHD and comorbid substance use disorder?].

Authors:  G Paslakis; F Kiefer; A Diehl; B Alm; E Sobanski
Journal:  Nervenarzt       Date:  2010-03       Impact factor: 1.214

10.  Childhood attention-deficit/hyperactivity disorder and the emergence of personality disorders in adolescence: a prospective follow-up study.

Authors:  Carlin J Miller; Janine D Flory; Scott R Miller; Seth C Harty; Jeffrey H Newcorn; Jeffrey M Halperin
Journal:  J Clin Psychiatry       Date:  2008-09       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.